Suggested remit: To appraise the clinical and cost effectiveness of 3D collagen matrix (novocart 3D) within its marketing authorisation for treating articular cartilage defects of the knee.
Topic is suspended
 
Status Suspended
Decision Selected
Process TA
ID number 2707

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
01 February 2021 The Department for Health and Social Care has asked NICE to conduct an appraisal of Novocart 3D for treating articular cartilage defects of the knee. For information, the company have informed NICE that they have withdrawn their EMA Marketing Authorisation Application for this indication at this time to wait for promising follow-up data. Therefore NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties as and when the situation changes.
25 January 2021 Suspended. Topic is suspended
25 January 2021 The Department for Health and Social Care has asked NICE to conduct an appraisal of Novocart 3D for treating articular cartilage defects of the knee. For information, the company have informed NICE that they have withdrawn their EMA Marketing Authorisation Application for this indication at this time to wait for promising follow-up data. Therefore NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties as and when the situation changes.
15 June 2020 - 13 July 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual